2024
MIF contribution to progressive brain diseases
Matejuk A, Benedek G, Bucala R, Matejuk S, Offner H, Vandenbark A. MIF contribution to progressive brain diseases. Journal Of Neuroinflammation 2024, 21: 8. PMID: 38178143, PMCID: PMC10765708, DOI: 10.1186/s12974-023-02993-6.Peer-Reviewed Original ResearchConceptsBrain diseasesMultiple sclerosisAlzheimer's diseaseMacrophage migration inhibitory factorModulation of neuroinflammationNumerous neurologic diseasesMigration inhibitory factorProgressive brain diseaseNew therapeutic strategiesInflammatory mediatorsChronic inflammationAutoimmune diseasesVascular diseaseNervous system developmentNeurologic diseaseNeuroendocrine functionPsychiatric disordersTherapeutic strategiesEconomic burdenNeurological diseasesNew biomarkersInhibitory factorNeurodegenerative pathologiesDiseaseNovel therapeutics
2023
Urothelial Oxidative Stress and ERK Activation Mediate HMGB1-Induced Bladder Pain
Ye S, Mahmood D, Ma F, Leng L, Bucala R, Vera P. Urothelial Oxidative Stress and ERK Activation Mediate HMGB1-Induced Bladder Pain. Cells 2023, 12: 1440. PMID: 37408274, PMCID: PMC10217556, DOI: 10.3390/cells12101440.Peer-Reviewed Original ResearchConceptsHigh mobility group box 1Macrophage migration inhibitory factorBladder painOxidative stressDisulfide HMGB1Mobility group box 1MIF-deficient miceNovel potential therapeutic strategyMigration inhibitory factorGroup box 1Potential therapeutic strategyOxidative stress productionN-acetylcysteine amideERK activationIntravesical treatmentMicturition volumeMicturition parametersReceptor 4Mechanical thresholdPainTherapeutic strategiesBox 1Bladder tissueInhibitory factorWestern blot
2013
CD84 is a survival receptor for chronic lymphocytic leukemia cells (P2044)
Marom A, Binsky-Ehrenreich I, Sobotta M, Shvidel L, Berrebi A, Hazan-Halevy I, Kay S, Aloshin A, Sagi I, Goldenberg D, Leng L, Bucala R, Herishanu Y, Haran M, Shachar I. CD84 is a survival receptor for chronic lymphocytic leukemia cells (P2044). The Journal Of Immunology 2013, 190: 132.12-132.12. DOI: 10.4049/jimmunol.190.supp.132.12.Peer-Reviewed Original ResearchChronic lymphocytic leukemiaMacrophage migration inhibitory factorBone marrowAbstract Chronic lymphocytic leukemiaChronic lymphocytic leukemia cellsMigration inhibitory factorCLL cell survivalNovel therapeutic strategiesLymphocytic leukemia cellsCD84 expressionPeripheral bloodLymphoid organsMcl-1 expressionClinical trialsLymphocytic leukemiaCLL cellsTherapeutic strategiesB lymphocytesMalignant cellsInhibitory factorInduces cell deathSurvival receptorCD84Leukemia cellsProtein levels
1998
Neuroimmunomodulation by Macrophage Migration Inhibitory Factor (MIF)
BUCALA R. Neuroimmunomodulation by Macrophage Migration Inhibitory Factor (MIF). Annals Of The New York Academy Of Sciences 1998, 840: 74-82. PMID: 9629239, DOI: 10.1111/j.1749-6632.1998.tb09551.x.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorMigration inhibitory factorImmune responseRole of MIFInhibitory factorT cell cytokine productionAnti-inflammatory propertiesAnterior pituitary cellsT-lymphocyte factorSteroid therapyLymph nodesCytokine productionImmunosuppressive effectsInflammatory conditionsGlucocorticoid actionT cellsFirst cytokineInflammatory sitesTherapeutic strategiesProinflammatory stimuliPituitary cellsImmune systemLymphocyte factorsGlucocorticoidsInhibitory effect